Prosecution Insights
Last updated: August 16, 2026
Application No. 17/206,835

ORGANIC ELECTROLUMINESCENT COMPOUND, ORGANIC ELECTROLUMINESCENT MATERIAL COMPRISING THE SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE

Final Rejection §102
Filed
Mar 19, 2021
Priority
Mar 20, 2020 — RE 10-2020-0034422 +2 more
Examiner
KUCKLA, ANNA GRACE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Rohm and Haas Electronic Materials Korea Ltd.
OA Round
4 (Final)
52%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 52% of resolved cases
52%
Career Allowance Rate
22 granted / 42 resolved
-7.6% vs TC avg
Strong +55% interview lift
Without
With
+55.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
53 currently pending
Career history
86
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
32.4%
-7.6% vs TC avg
§102
23.9%
-16.1% vs TC avg
§112
23.6%
-16.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 42 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 1-22 are pending in the instant application. Claims 1 and 9 are amended via the amendment filed June 16th, 2026 and claims 4 and 10-22 are withdrawn. Priority Acknowledgment is made of applicant’s claim for foreign priority based on applications KR10-2020-0034422 filed on 03/20/2020, KR10-2020-0147603 filed on 11/06/2020, and KR10-2021-0022715 filed on 02/19/2021. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Withdrawn Rejections Applicant’s arguments, filed June 16th, 2026, with respect to 102 rejection have been fully considered and are persuasive. The 102 rejection of claims 1-3 and 5-8 has been withdrawn. Applicant has overcome this rejection by amending claim 1 to remove the option for R6 to represent –(La)a-(Ar1)b. Response to Remarks Applicant’s arguments with respect to the 102 rejection of claims 1-3 and 5-8 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Restriction/Election Applicant’s election without traverse of compound C-14 in the reply filed on November 20th, 2024 is acknowledged. Applicant’s elected species appears free of the prior art. Therefore, the search and examination has been extended according to MPEP 803.02 to include the structural species: PNG media_image1.png 160 279 media_image1.png Greyscale . Since a non-elected species has been found not allowable over the prior art, examination has been limited to claims directed to the elected species, which are presently claims 1-3 and 5-9. Claims 1-3 and 5-9 have been examined to the extent that they are readable on the elected embodiment and the above identified nonelected species. Since the nonelected species has been found not allowable, subject matter not embraced by the elected embodiment or the above identified nonelected species is therefore withdrawn from further consideration. Claims 4 and 10-22 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention or species. Election was made without traverse in reply filed November 20th, 2024. New Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1-3 and 5-8 are newly rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Saito et al (US 2017/0256726 A1, published September 7th, 2017), as necessitated by Applicant’s amendments. Saito teaches the following compound (page 79, compound L3): PNG media_image1.png 160 279 media_image1.png Greyscale . Regarding claim 1, this compound is embraced by instant formula 1, wherein R1-R4 are (C1-C30)alkyl, R5, R12 and R6-R10 are hydrogen and R11 ais –(L1)a-(Ar1)b, wherein L1 is a single bond, a is 1, b is 1, and Ar1 is heteroaryl. Regarding claim 2, L1 is a single bond and Ar1 is heteroaryl containing one N. Regarding claim 3, the compound above is of formula (1-2). Regarding claim 5, L1 is a single bond. Regarding claim 6, Ar1 is a substituted pyridyl. Regarding claim 7, Ar1 in the compound above is heteroaryl and as such, the limitations of the claim regarding the (C6-C30) aryl do not apply to the compound, thus the compound reads on the claim. Regarding claim 8, Ar1 in the compound above is heteroaryl and as such, the limitations of the claim regarding Ar2 and Ar3 of -N-(Ar2)(Ar3) do not apply to the compound, thus the compound reads on the claim. Conclusion Claims 1-3 and 5-8 are rejected. Claims 4 and 10-22 are withdrawn. Claim 9 is allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anna Grace Kuckla whose telephone number is (703)756-5610. The examiner can normally be reached Monday-Friday 7:30-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at (571)270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.G.K./Examiner, Art Unit 1626 /FEREYDOUN G SAJJADI/Supervisory Patent Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Show 2 earlier events
Feb 14, 2025
Non-Final Rejection mailed — §102
Aug 12, 2025
Response Filed
Nov 17, 2025
Final Rejection mailed — §102
Mar 10, 2026
Request for Continued Examination
Mar 16, 2026
Response after Non-Final Action
Mar 23, 2026
Non-Final Rejection mailed — §102
Jun 16, 2026
Response Filed
Jul 14, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12692230
(1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer
3y 8m to grant Granted Jul 28, 2026
Patent 12679844
IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS
3y 5m to grant Granted Jul 14, 2026
Patent 12624004
OPIOID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
4y 0m to grant Granted May 12, 2026
Patent 12583875
PYRROMETHENE-BORON COMPLEX, COLOR CONVERSION COMPOSITION, COLOR CONVERSION FILM, LIGHT SOURCE UNIT, DISPLAY, AND ILLUMINATION DEVICE
4y 2m to grant Granted Mar 24, 2026
Patent 12577273
SMALL MOLECULE MODULATORS OF GUT BACTERIAL BILE ACID METABOLISM
4y 4m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
52%
Grant Probability
99%
With Interview (+55.0%)
3y 4m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 42 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month